Radiation-recall skin disorders associated with the use of antineoplastic drugs: Pathogenesis, prevalence, and management

American Journal of Clinical Dermatology

Volumn 1, Issue 2, 2000, Pages 113-116

  Winnie, Yeo ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CASE REPORT; FEMALE; HUMAN; MIDDLE AGED; PREVALENCE; RADIATION DERMATITIS; REVIEW;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; PREVALENCE; RADIODERMATITIS;

EID: 0039770572     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001020-00006     Document Type: Review

References (31)

1. Eifel PJ, McClure S. Severe chemotherapy-induced recall of radiation mucositis in a patient with non-Hodgkin's lymphoma of Waldeyer's ring [letter]. Int J Radiat Oncol Biol Phys 1989; 17: 907-8
2. Mcinerney DP, Bullimore J. Reactivation of radiation pneumonitis by adriamycin. Br J Radiol 1977; 50: 224-7
3. Cassady JR, Richter MT, Piro AJ, et al. Radiation-adriamycin interactions: preliminary clinical observations. Cancer 1975; 36: 946-9
4. Kellie SJ, Plowman PN, Malpas JS. Radiation recall and radiosensitization with alkylating agents. Lancet 1987; 1 (8542): 1149-50
5. Donaldson SS, Click JM, Wilbur JR. Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 1974; 81: 407-8
6. Redpath JL, Cloman M. The effect of adriamycin and actinomycin D on radiation-induced skin reactions in mouse feet. Int J Radiat Oncol Biol Phys 1979; 5: 483-6
7. D'Angio GJ, Farber S, Maddock CL. Potentiation of X-ray effects by actinomycin D. Radiology 1959; 73: 175-7
8. Pui CH, de Graaf SSN, Dow LW, et al. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. Cancer Res 1998; 48: 5348-2
9. Steizer KJ, Griffin TW, Koh WJ. Radiation recall skin toxicity with bleomycin in a patient with Kaposi sarcoma related to acquired immune deficiency syndrome. Cancer 1993; 71: 1322-5
10. Von Essen CF, Kilgerman MM, Calbresi P. Radiation and 5-fluorouracil: a controlled clinical study. Radiology 1963; 81: 1018-27
11. Nemechek PM, Corder MC. Radiation recall associated with vinblastine in a patient treated for Kaposi sarcoma related with Acquired Immune Deficiency Syndrome. Cancer 1992; 70: 1605-6
12. Sears ME. Erythema in areas of previous irradiation in patients treated with hydroxyurea (NSC-32065). Cancer Chemother Rep 1964; 40: 31-2
13. Jolivet J, Landry L, Pinard MF, et al. A Phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother Pharmacol 1987; 20: 169-72
14. Fontana JA. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep 1979; 63: 224-5
15. Phillips KA, Urch M, Bishop JF. Radiation-recall dermatitis in a patient treated with paclitaxel. J Clin Oncol 1995; 13: 305
16. Shenkier T, Gelmon K. Paclitaxel and radiation recall dermatitis. J Clin Oncol 1994; 12: 439
17. Yeo W, Leung SF, Johnson PJ. Radiation-recall dermatitis with docetaxel: establishment of a requisite radiation threshold. Eur J Cancer 1997; 33 (4): 698-99
18. Philips TL, Fu KK. Quantification of combined radiation therapy and chemotherapy affects on critical normal tissues. Cancer 1976; 37: 1186-200
19. Fu KK. Normal tissue effects of combined radiotherapy and chemotherapy for head and neck cancer. Front Radiat Ther Oncol 1979; 13: 113-32
20. Cantril ST. Audience interaction. Front Radiat Ther Oncol 1979; 13: 145-6
21. Danjoux CE. Delayed complications following combination of radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1979; 5: 441-3
22. Philips TL, Wharam MD, Margolis LW. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 1975; 34: 1678-84
23. Busch D. Genetic susceptibility to radiation and chemotherapy injury: diagnosis and management. Int J Radiat Oncol Biol Phys 1994; 30: 997-1002
24. West CM, Elyan SA, Berry P, et al. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients and individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes. Int J Radiat Oncol Biol Phys 1995; 68: 197-203
25. Jongmans W, Artuso M, Vuillaume M, et al. The role of ataxia-telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionizing radiation. Oncogene 1996; 13: 1133-8
26. Opptiz U, Bernthaler U, Schindler D, et al. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 1999; 44: 981-8
27. Tan CTC, Dargeon HW, Burchenal JH. The effect of actinomycin D on cancer in childhood. Pediatric 1959; 24: 544-61
28. Seymour CB, Mothersill Q, Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol 1986; 50: 167-79
29. Hellman S, Botnick LE. Skin cell depletion, an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 1977; 2: 181-4
30. Tsichler RB, Schiff PB, Geard CR, et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613-17
31. Kitani H, Kosaka T, FukMara T, et al. The 'recall effect' in radiotherapy: is subeffective, reparable damage responsible? Int J Radiat Oncol Biol Phys 1990; 18: 689-95